Appili Therapeutics Inc. reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported revenue was CAD 0.009349 million compared to CAD 1.4 million a year ago. Net loss was CAD 2.62 million compared to CAD 3.24 million a year ago. Basic loss per share from continuing operations was CAD 0.02 compared to CAD 0.05 a year ago.
For the nine months, revenue was CAD 0.023274 million compared to CAD 1.42 million a year ago. Net loss was CAD 6.58 million compared to CAD 21.78 million a year ago. Basic loss per share from continuing operations was CAD 0.06 compared to CAD 0.33 a year ago.